+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

B-cell Non-Hodgkin's Lymphoma - Market Insights, Epidemiology, and Market Forecast - 2028

  • ID: 4911969
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 287 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Epizyme
  • Hoffmann-La Roche
  • Merck
  • Novartis
  • MORE
The ‘B-cell Non-Hodgkin’s Lymphoma - Market Insights, Epidemiology, and Market Forecast - 2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of B-cell NHL in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017–2028.

B-cell NHL - Disease Understanding and Treatment Algorithm

NHL is a type of blood cancer that initially started in the white blood cells (WBCs) called lymphocytes, it is also known as non-Hodgkin’s disease. Commonly the NHL occurs from lymph node at one or more places in the body, which can progress through the lymphatic system from one group of lymph nodes to another. It can progress to other lymph tissue, particularly in the bone marrow and spleen, or to lymph nodes in the liver.

NHL represents a heterogeneous group of malignancies of different biology and prognosis. It can occur at any age and are often marked by enlarged lymph nodes, fever, night sweats, and weight loss. There are different types of, and these are divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can develop from either B-cells or T-cells. Lymphomas that occur after allogeneic bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas and are collectively known as post-transplant lymph proliferative disorders.

B-cells or B lymphocytes help to protect the body against bacteria and viruses by making proteins called antibodies. Most of the cases of NHL are B-cell NHL. The exact cause of NHL is unknown but the factors that can increase the risk of developing the conditions are weakening of immune system, continuous uptake of immunosuppressant medication, and previous exposure of common virus-like Epstein-Barr virus. The diagnosis of NHL is mainly done by carrying out a biopsy. If it is confirmed by biopsy then further it is tested by a blood test, chest X-ray, CT scan, MRI Scan, PET scan, and Lumbar puncture, etc.

On the basis of diagnosis the treatment is done which includes chemotherapy, radiation therapy, targeted therapy, immunotherapy such as monoclonal antibodies, immune checkpoint inhibitors, and CAR T cells, and stem cell transplantation/bone marrow transplantation.

B-cell NHL Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of NHL, Total Incidence cases of B cell-NHL, Gender-specific Incidence of B-cell NHL, Age-specific Incidence of B-cell NHL, Subtype - Specific Incidence of B-cell NHL and Stage-Specific Incidence of B-cell NHL] scenario of B-cell NHL in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2028.

Analysts have assessed that the total prevalent population of B-cell NHL in the 7MM was 141,873 in 2017. In addition to this, there was a gender difference in the disease. It was seen that, the B-cell lymphoma cases occurs more frequently in male population as compared to female. In 2017, a more number of males were affected by the disease, i.e., 55% of the B-cell NHL cases in the 7MM, which is equivalent to 78,030 cases in comparison to the females.

B-cell NHL Drug Chapters

The treatment of B-cell NHL is mainly based on the subtype and stage of the disease, according to the subtype and stage of the disease, initial therapy and intensity of treatment taken into consideration. In general, the goal of treatment is to destroy as many lymphoma cells as possible and to induce complete remission. Treatment can also keep non-Hodgkin lymphoma (NHL) in check for many years, even though imaging or other studies show the remaining sites of disease. This situation may be referred to as a “partial remission.”

For patients without symptoms and with indolent subtypes of B-cell NHL, the treatment may be the watch-and-wait approach, meaning treatment is deferred or delayed until signs of disease progression occur. Frequent and careful observation is required so that effective treatment can be started if the disease starts advancing. Some patients have a long-time slow-growing disease, while others have a condition that evolves (transforms) into a more aggressive type of B-cell NHL that requires immediate treatment.

In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell NHL. Although radiation therapy is often neither the sole nor the principal curative therapy, it is an important additional treatment in some cases.

The current treatment approaches include Rituximab based mono and combination therapies, Monoclonal antibodies based regimen except Rituximab, Immune Checkpoint inhibitors, Immunomodulators, Proteasome inhibitors, Kinase inhibitors, CAR-T cell therapies, and Histone deacetylase (HDAC) inhibitors.

The following drugs are approved under abovementioned classes, Brukinsa (Zanubrutinib, a product of BeiGene), Polivy (Polatuzumab vedotin, a product of Hoffmann-La Roche), Venetoclax (ABT199, a product of AbbVie and Roche), Kymriah (tisagenlecleucel, a product of Novartis), Yescarta (Axicabtagene ciloleucel, a product of Gilead Sciences), Aliqopa (Copanlisib, a product of Bayer), Imbruvica (Ibrutinib, a product of Janssen/Pharmacyclics (AbbVie Company)), Zydelig (Idelalisib, a product of Gilead Sciences), Gazyva (Obinutuzumab, a product of Genentech, Roche Group), Zevalin (ibritumomab tiuxetan, a product of Spectrum Pharmaceuticals), Velcade (bortezomib, a product of Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical), Revlimid (lenalidomide, a product of Celgene Corporation) and others.

B-cell NHL Market Outlook

The market size of B-cell NHL in seven major markets (7MM) is estimated to be USD 4,103 million in 2017. The United States accounts for the highest market size of B-cell NHL in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while Spain had the lowest market size of B-cell NHL in 2017.

B-cell NHL Drugs Uptake

With the launch of emerging therapies like Lisocabtagene maraleucel (JCAR017, a product of Bristol-Myers Squibb), which is an anti-CD-19-directed CAR T-cell product administered intravenously in defined composition at a precise dose of CD8 and CD4 CAR T cells which induced durable responses in poor-prognosis patients with R/R aggressive NHL after at least two prior therapies, KTE-X19 (Gilead Sciences), Tafasitamab (MOR208, a product of MorphoSys AG), Tazemetostat (E7438, a product of Epizyme), Abexinostat (Xynomic Pharmaceuticals), Umbralisib (TG Therapeutics), Avelumab (Pfizer/Merck) and others, the market of B-cell NHL is anticipated to change during the forecast period (2019–2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by Analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of B-cell NHL will have better management practices.

According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019–2028], and with their anticipated launch, the market size of B-cell NHL will also experience significant growth.

B-cell NHL Report Insights
  • Total Incidence of NHL
  • Total Incidence cases of B cell-NHL
  • Gender-specific Incidence of B-cell NHL
  • Age-specific Incidence of B-cell NHL
  • Subtype - Specific Incidence of B-cell NHL
  • Stage-Specific Incidence of B-cell NHL
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

B-cell NHL Report Key Strengths
  • 10–Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

B-cell NHL Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving B-cell NHL market
  • Organize sales and marketing efforts by identifying the best opportunities for B-cell NHL market
  • To understand the future market competition in the B-cell NHL market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Epizyme
  • Hoffmann-La Roche
  • Merck
  • Novartis
  • MORE

1. Key Insights

2. Executive Summary of B-cell NHL

3. SWOT Analysis for B-cell NHL

4. B-cell NHL: Patient Share of B-cell NHL at a Glance
4.1. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2017
4.2. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2028
4.3. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2017
4.4. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2028

5. B-cell NHLs: Market Overview at a Glance
5.1. Total Market Share (%) Distribution of B-cell NHL in 2017
5.2. Total Market Share (%) Distribution of B-cell NHL in 2028

6. B-cell Non-Hodgkin Lymphoma (NHL): Disease Background and Overview
6.1. Types of B-cell NHL
6.1.1. Diffuse large B-cell lymphoma (DLBCL)
6.1.2. Burkitt Lymphoma (BL)
6.1.3. Mantle Cell Lymphoma (MCL)
6.1.4. Follicular Lymphoma (FL)
6.1.5. Marginal Zone Lymphoma (MZL)
6.1.6. Chronic Lymphocytic Leukemia (CLL) and Small-Cell Lymphocytic Lymphoma (SLL)
6.2. Origin and Pathogenesis of B-cell NHL
6.2.1. Genetic Lesions in the Pathogenesis of B-cell Lymphomas
6.2.2. Microenvironmental Interactions in B-Cell Lymphomas and the Role of the BCR
6.3. Risk Factors for NHL
6.4. Staging for B-cell NHL
6.4.1. Staging of NHL in Adults
6.4.2. Staging of NHL in Children
6.4.3. Staging Systems for Chronic Lymphocytic Lymphoma (CLL)
6.5. Survival Rate for NHL (5-year)
6.6. Diagnosis of NHL
6.6.1. Diagnostic Algorithm for B-cell NHL
6.6.2. Evaluation
6.6.3. Testing Strategies to Diagnose B-cell Lymphomas
6.6.4. Stratification of High-Grade B-cell Lymphomas Using Laboratory Techniques
6.6.5. Summary of Recommendations for Diagnosis and pathology/molecular biology (DLBCL): European Society for Medical Oncology (ESMO)

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM

8. Epidemiology Scenario: 7MM
8.1. Total Incidence of NHL in the 7MM
8.1.1. Total Incidence cases of B cell-NHL in the 7MM
8.1.2. Gender-specific Incidence of B-cell NHL in the 7MM
8.1.3. Age-specific Incidence of B-cell NHL in the 7MM
8.1.4. Subtype - Specific Incidence of B-cell NHL in the 7MM
8.1.5. Stage-Specific Incidence of B-cell NHL in the 7MM

9. United States Epidemiology
9.1. Total Incidence cases of B cell-NHL in the United States
9.2. Age-specific Incidence of B-cell NHL in the United States
9.3. Subtype-Specific Incidence of B-cell NHL in the United States
9.4. Stage-Specific Incidence of B-cell NHL in the United States

10. EU-5 Country-wise Epidemiology
10.1. Germany Epidemiology
10.1.1. Total Incidence cases of B cell-NHL in Germany
10.1.2. Age-specific Incidence of B-cell NHL in Germany
10.1.3. Subtype-Specific Incidence of B-cell NHL in Germany
10.1.4. Stage-Specific Incidence of B-cell NHL in Germany
10.2. France Epidemiology
10.2.1. Total Incidence cases of B cell-NHL in France
10.2.2. Age-specific Incidence of B-cell NHL in France
10.2.3. Subtype-Specific Incidence of B-cell NHL in France
10.2.4. Stage-Specific Incidence of B-cell NHL in France
10.3. Italy Epidemiology
10.3.1. Total Incidence cases of B cell-NHL in Italy
10.3.2. Age-specific Incidence of B-cell NHL in Italy
10.3.3. Subtype-Specific Incidence of B-cell NHL in Italy
10.3.4. Stage-Specific Incidence of B-cell NHL in Italy
10.4. Spain Epidemiology
10.4.1. Total Incidence cases of B cell-NHL in Spain
10.4.2. Age-specific Incidence of B-cell NHL in Spain
10.4.3. Subtype-Specific Incidence of B-cell NHL in Spain
10.4.4. Stage-Specific Incidence of B-cell NHL in Spain
10.5. United Kingdom Epidemiology
10.5.1. Total Incidence cases of B cell-NHL in the United Kingdom
10.5.2. Age-specific Incidence of B-cell NHL in the United Kingdom
10.5.3. Subtype-Specific Incidence of B-cell NHL in the United Kingdom
10.5.4. Stage-Specific Incidence of B-cell NHL in the United Kingdom

11. Japan Epidemiology
11.1. Total Incidence cases of B cell-NHL in Japan
11.2. Age-specific Incidence of B-cell NHL in Japan
11.3. Subtype-Specific Incidence of B-cell NHL in Japan
11.4. Stage-Specific Incidence of B-cell NHL in Japan

12. Current Treatment Practices for B-cell NHL: As per Leukemia & Lymphoma Society (LLS)
12.1. Treatment Overview
12.1.1. Factors That Influence Treatment
12.1.2. The International Prognostic Index (IPI)
12.1.3. Treatment Considerations for Children, Adolescents, and Young Adults
12.2. Treatment of B-cell NHL Subtypes
12.2.1. Diffuse Large B-Cell Lymphoma (DLBCL)
12.2.2. Burkitt Lymphoma
12.2.3. Mantle Cell Lymphoma (MCL)
12.2.4. Follicular Lymphoma (FL)
12.2.5. Marginal Zone Lymphoma (MZL)
12.2.6. Small-Cell Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL)

13. Unmet Needs

14. Marketed Products
14.1. Brukinsa (Zanubrutinib): BeiGene
14.1.1. Product Description
14.1.2. Regulatory Milestones
14.1.3. Other Developmental Activities
14.1.4. Pivotal Clinical Trials
14.1.5. Ongoing Clinical Trials
14.2. Polivy (Polatuzumab vedotin): Hoffmann-La Roche
14.2.1. Product Description
14.2.2. Regulatory Milestones
14.2.3. Other Developmental Activities
14.2.4. Pivotal Clinical Trials
14.2.5. Ongoing Current Pipeline Activity
14.3. Venetoclax (ABT199): AbbVie and Roche
14.3.1. Product Description
14.3.2. Regulatory Milestones
14.3.3. Other Developmental Activities
14.3.4. Pivotal Clinical Trials
14.3.5. Ongoing Clinical Trials
14.4. Kymriah (tisagenlecleucel): Novartis
14.4.1. Product Description
14.4.2. Regulatory Milestones
14.4.3. Other Developmental Activities
14.4.4. Pivotal Clinical Trials
14.4.5. Ongoing Current Pipeline Activity
14.5. Copiktra (Duvelisib): Verastem
14.5.1. Product Description
14.5.2. Regulatory Milestones
14.5.3. Other Developmental Activities
14.5.4. Pivotal Clinical Trials
14.6. Keytruda (Pembrolizumab): Merck Sharp & Dohme
14.6.1. Product Description
14.6.2. Regulatory Milestones
14.6.3. Pivotal Clinical Trials
14.6.4. Ongoing Current Pipeline Activity
14.7. Yescarta (Axicabtagene ciloleucel; KTE-C19): Gilead Sciences
14.7.1. Product Description
14.7.2. Regulatory Milestones
14.7.3. Other Developmental Activities
14.7.4. Pivotal Clinical Trials
14.7.5. Ongoing Current Pipeline Activity
14.8. Aliqopa (Copanlisib; BAY 80-6946): Bayer
14.8.1. Product Description
14.8.2. Regulatory Milestones
14.8.3. Other Developmental Activities
14.8.4. Pivotal Clinical Trials
14.8.5. Ongoing Current Pipeline Activity
14.9. Calquence (Acalabrutinib): AstraZeneca
14.9.1. Product Description
14.9.2. Regulatory Milestones
14.9.3. Other Dvelopmental Activities
14.9.4. Pivotal Clinical Trials
14.9.5. Ongoing Clinical Trials
14.10. Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company)
14.10.1. Product Description
14.10.2. Regulatory Milestones
14.10.3. Other Developmental Activities
14.10.4. Pivotal Clinical Trials
14.10.5. Ongoing Current Pipeline Activity
14.11. Zydelig (Idelalisib): Gilead Sciences
14.11.1. Product Description
14.11.2. Regulatory Milestones
14.11.3. Other Developmental Activities
14.11.4. Pivotal Clinical Trials
14.11.5. Ongoing Current Pipeline Activity
14.12. Gazyva (Obinutuzumab, GA-101): Genentech (Roche Group)
14.12.1. Product Description
14.12.2. Regulatory Milestones
14.12.3. Other Developmental Activities
14.12.4. Pivotal Clinical Trials
14.12.5. Ongoing Current Pipeline Activity
14.13. Revlimid (lenalidomide): Celgene Corporation
14.13.1. Product Description
14.13.2. Regulatory Milestones
14.13.3. Other Developmental Activities
14.13.4. Pivotal Clinical Trials
14.13.5. Ongoing Clinical Trials
14.14. Velcade (bortezomib): Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical
14.14.1. Product Description
14.14.2. Regulatory Milestones
14.14.3. Other Developmental Activities
14.14.4. Pivotal Clinical Trials
14.14.5. Ongoing Current Pipeline Activity
14.15. Zevalin (ibritumomab tiuxetan): Spectrum Pharmaceuticals
14.15.1. Product Description
14.15.2. Regulatory Milestones
14.15.3. Other Developmental Activities
14.15.4. Pivotal Clinical Trials
14.16. Torisel: Pfizer
14.16.1. Product Description
14.16.2. Regulatory Milestones
14.16.3. Pivotal Clinical Trials

15. Emerging Therapies
15.1. Key Cross
15.2. Tafasitamab (MOR208; formerly XmAb 5574): MorphoSys AG
15.2.1. Product Description
15.2.2. Other Developmental Activities
15.2.3. Clinical Development
15.2.4. Safety and Efficacy
15.3. Lisocabtagene maraleucel (JCAR017): Bristol-Myers Squibb
15.3.1. Product Description
15.3.2. Other Developmental Activities
15.3.3. Clinical Development
15.3.4. Safety and Efficacy
15.4. Enzastaurin Hydrochloride (DB102): Denovo Biopharma
15.4.1. Product Description
15.4.2. Other Developmental Activities
15.4.3. Clinical Development
15.4.4. Safety and Efficacy
15.5. Avelumab (Bavencio): Pfizer/Merck
15.5.1. Product Description
15.5.2. Other Developmental Activities
15.5.3. Clinical Development
15.6. Umbralisib (TG-1202): TG Therapeutics
15.6.1. Product Description
15.6.2. Other Developmental Activities
15.6.3. Clinical Development
15.6.4. Safety and Efficacy

16. B-cell NHL: Seven Major Market Analysis
16.1. Key Findings
16.2. Total Market Size of B-cell NHL in the 7MM
16.3. Market Size of B-cell NHL by Therapeutic Class in the 7MM

17. Market Outlook: 7MM

18. United States Market Size
18.1. Total Market size of B-cell NHL in the United States
18.2. Market Size of B-cell NHL by Line of Therapies in the US

19. EU-5 Market Size
19.1. Germany Market Size
19.1.1. Total Market size of B-cell NHL in Germany
19.1.2. Market Size of B-cell NHL by Line of Therapies in Germany
19.2. France Market Size
19.2.1. Total Market size of B-cell NHL in France
19.2.2. Market Size of B-cell NHL by Therapies in France
19.3. Italy Market Size
19.3.1. Total Market size of B-cell NHL in Italy
19.3.2. Market Size of B-cell NHL by Line of Therapies in Italy
19.4. Spain Market Size
19.4.1. Total Market size of B-cell NHL in Spain
19.4.2. Market Size of B-cell NHL by Line of Therapies in Spain
19.5. United Kingdom Market Size
19.5.1. Total Market size of B-cell NHL in the United Kingdom
19.5.2. Market Size of B-cell NHL by Line of Therapies in the United Kingdom

20. Japan Market Size
20.1. Total Market size of B-cell NHL in Japan
20.2. Market Size of B-cell NHL by Therapies in Japan

21. Market Access and Reimbursement Scenario of B-cell NHL Therapies
21.1. CAR-T cell Therapies

22. Market Drivers

23. Market Barriers

24. Appendix
24.1. Bibliography
24.2. Report Methodology

25. Disclaimer

26. Researcher Capabilities

27. About the Publisher

List of Tables:
Table 1 Summary of B-cell NHL Market, Epidemiology, and Key Events (2017–2028)
Table 2 Stage-wise Survival Rate of DLBCL
Table 3 Stage wise Survival Rate of FL
Table 4 Stage wise Survival Rate of MZL
Table 5 Genetic Lesions in Human B-cell Lymphomas
Table 6 Rai Staging System
Table 7 Binet Staging System
Table 8 Major Sources Used
Table 9 Total Incidence of NHL in the 7MM (2017–2028)
Table 10 Total Incidence cases of B cell-NHL in the 7MM (2017–2028)
Table 11 Gender-specific Incidence of B-cell NHL in the 7MM (2017–2028)
Table 12 Age-specific Incidence of B-cell NHL in the 7MM (2017–2028)
Table 13 Subtype - Specific Incidence of B-cell NHL in the 7MM (2017–2028)
Table 14 Stage-Specific Incidence of B-cell NHL in the 7MM (2017–2028)
Table 15 Total Incidence cases of B cell-NHL in the United States (2017–2028)
Table 16 Age-specific Incidence of B-cell NHL in the United States (2017–2028)
Table 17 Subtype - Specific Incidence of B-cell NHL in the United States (2017–2028)
Table 18 Stage-Specific Incidence of B-cell NHL in the United States (2017–2028)
Table 19 Total Incidence cases of B cell-NHL in Germany (2017–2028)
Table 20 Age-specific Incidence of B-cell NHL in Germany (2017–2028)
Table 21 Subtype - Specific Incidence of B-cell NHL in Germany (2017–2028)
Table 22 Stage-Specific Incidence of B-cell NHL in Germany (2017–2028)
Table 23 Total Incidence cases of B cell-NHL in France (2017–2028)
Table 24 Age-specific Incidence of B-cell NHL in France (2017–2028)
Table 25 Subtype - Specific Incidence of B-cell NHL in France (2017–2028)
Table 26 Stage-Specific Incidence of B-cell NHL in France (2017–2028)
Table 27 Total Incidence cases of B cell-NHL in Italy (2017–2028)
Table 28 Age-specific Incidence of B-cell NHL in Italy (2017–2028)
Table 29 Subtype - Specific Incidence of B-cell NHL in Italy (2017–2028)
Table 30 Stage-Specific Incidence of B-cell NHL in Italy (2017–2028)
Table 31 Total Incidence cases of B cell-NHL in Spain (2017–2028)
Table 32 Age-specific Incidence of B-cell NHL in Spain (2017–2028)
Table 33 Subtype - Specific Incidence of B-cell NHL in Spain (2017–2028)
Table 34 Stage-Specific Incidence of B-cell NHL in Spain (2017–2028)
Table 35 Total Incidence cases of B cell-NHL in the United Kingdom ( (2017–2028)
Table 36 Age-specific Incidence of B-cell NHL in the United Kingdom (2017–2028)
Table 37 Subtype - Specific Incidence of B-cell NHL in the United Kingdom (2017–2028)
Table 38 Stage-Specific Incidence of B-cell NHL in the United Kingdom (2017–2028)
Table 39 Total Incidence cases of B cell-NHL in Japan (2017–2028)
Table 40 Age-specific Incidence of B-cell NHL in Japan (2017–2028)
Table 41 Subtype - Specific Incidence of B-cell NHL in Japan (2017–2028)
Table 42 Stage-Specific Incidence of B-cell NHL in Japan (2017–2028)
Table 43 Polivy, Clinical Trial Description, 2019
Table 44 Keytruda, Clinical Trial Description, 2019
Table 45 Gazyva, Clinical Trial Description, 2019
Table 46 Yescarta, Clinical Trial Description, 2019
Table 47 Aliqopa, Clinical Trial Description, 2019
Table 48 Ibrutinib, Clinical Trial Description, 2019
Table 49 Imbruvica, Clinical Trial Description, 2019
Table 50 Imbruvica, Clinical Trial Description, 2019
Table 51 Imbruvica, Clinical Trial Description, 2019
Table 52 Zydelig, Clinical Trial Description, 2019
Table 53 Gazyva, Clinical Trial Description, 2019
Table 54 Gazyva, Clinical Trial Description, 2019
Table 55 Velcade, Clinical Trial Description, 2019
Table 56 Emerging Drugs Key cross Competition
Table 57 Tafasitamab, Clinical Trial Description, 2019
Table 58 JCAR017, Clinical Trial Description, 2019
Table 59 Enzastaurin Hydrochloride (DB102) , Clinical Trial Description, 2019
Table 60 Avelumab , Clinical Trial Description, 2019
Table 61 Umbralisib (TGR-1202), Clinical Trial Description, 2019
Table 62 7MM Market Size of B-cell NHL in USD Million (2017–2028)
Table 63 7MM Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 64 List of Few Marketed Products with their respective Therapeutic Classes
Table 65 US Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 66 US Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028)
Table 67 US Market Size of B-cell NHL of Relapsed/ Refractory in USD Million (2017–2028)
Table 68 Germany Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 69 Germany Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028)
Table 70 Germany Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028)
Table 71 France Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 72 France Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028)
Table 73 France Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028)
Table 74 Italy Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 75 Italy Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028)
Table 76 Italy Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028)
Table 77 Spain Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 78 Spain Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028)
Table 79 Spain Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028)
Table 80 United Kingdom Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 81 United Kingdom Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028)
Table 82 United Kingdom Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028)
Table 83 Japan Market Size of B-cell NHL By Class in USD Million (2017–2028)
Table 84 Japan Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028)
Table 85 Japan Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028)
Table 86 HTA Assessment in the EU-5 Countries

List of Figures:
Figure 1 B-cell NHL SWOT Analysis
Figure 2 B-cell Development
Figure 3 Germinal Center Reaction and Cellular Origin of Human B-cell Lymphomas
Figure 4 Location of Non-Hodgkin Lymphoma in the Body for Stage 1
Figure 5 Location of Non-Hodgkin Lymphoma in the Body for Stage 2
Figure 6 Location of Non-Hodgkin Lymphoma in the Body for Stage 3
Figure 7 Location of Non-Hodgkin Lymphoma in the Body for Stage 4
Figure 8 Survival Rate for NHL
Figure 9 NHL 5-Year Relative Survival by Stage at Diagnosis
Figure 10 Diagnostic Algorithm for Major B-cell Lymphomas
Figure 11 Additional Tests for NHL
Figure 12 Global Heat Map of NHL
Figure 13 Total Incidence of NHL in the 7MM (2017–2028)
Figure 14 Total Incidence cases of B cell-NHL in the 7MM (2017–2028)
Figure 15 Gender-specific Incidence of B-cell NHL in the 7MM (2017–2028)
Figure 16 Age-specific Incidence of B-cell NHL in the 7MM (2017–2028)
Figure 17 Subtype - Specific Incidence of B-cell NHL in the 7MM (2017–2028)
Figure 18 Stage-Specific Incidence of B-cell NHL in the 7MM (2017–2028)
Figure 19 Total Incidence cases of B cell-NHL in the United States (2017–2028)
Figure 20 Age-specific Incidence of B-cell NHL in the United States (2017–2028)
Figure 21 Subtype - Specific Incidence of B-cell NHL in the United States (2017–2028)
Figure 22 Stage-Specific Incidence of B-cell NHL in the United States (2017–2028)
Figure 23 Total Incidence cases of B cell-NHL in Germany (2017–2028)
Figure 24 Age-specific Incidence of B-cell NHL in Germany (2017–2028)
Figure 25 Subtype - Specific Incidence of B-cell NHL in Germany (2017–2028)
Figure 26 Stage-Specific Incidence of B-cell NHL in Germany (2017–2028)
Figure 27 Total Incidence cases of B cell-NHL in France (2017–2028)
Figure 28 Age-specific Incidence of B-cell NHL in France (2017–2028)
Figure 29 Subtype - Specific Incidence of B-cell NHL in France (2017–2028)
Figure 30 Stage-Specific Incidence of B-cell NHL in France (2017–2028)
Figure 31 Total Incidence cases of B cell-NHL in Italy (2017–2028)
Figure 32 Age-specific Incidence of B-cell NHL in Italy (2017–2028)
Figure 33 Subtype - Specific Incidence of B-cell NHL in Italy (2017–2028)
Figure 34 Stage-Specific Incidence of B-cell NHL in Italy (2017–2028)
Figure 35 Total Incidence cases of B cell-NHL in Spain (2017–2028)
Figure 36 Age-specific Incidence of B-cell NHL in Spain (2017–2028)
Figure 37 Subtype - Specific Incidence of B-cell NHL in Spain (2017–2028)
Figure 38 Stage-Specific Incidence of B-cell NHL in Spain (2017–2028)
Figure 39 Total Incidence cases of B cell-NHL in the United Kingdom (2017–2028)
Figure 40 Age-specific Incidence of B-cell NHL in the United Kingdom (2017–2028)
Figure 41 Subtype - Specific Incidence of B-cell NHL in the United Kingdom (2017–2028)
Figure 42 Stage-Specific Incidence of B-cell NHL in the United Kingdom (2017–2028)
Figure 43 Total Incidence cases of B cell-NHL in Japan (2017–2028)
Figure 44 Age-specific Incidence of B-cell NHL in Japan (2017–2028)
Figure 45 Subtype - Specific Incidence of B-cell NHL in Japan (2017–2028)
Figure 46 Stage-Specific Incidence of B-cell NHL in Japan (2017–2028)
Figure 47 First Line Therapy Algorithm for DLBCL (Spanish Lymphoma Group (GELTAMO) Guidelines)
Figure 48 Treatment Algorithm for Patients with CLL/SLL
Figure 49 Unmet Needs of B-cell NHL
Figure 50 Market Size of B-cell NHL in the 7MM Countries in USD Million (2017–2028)
Figure 51 Market Size of B-cell NHL by therapies in the 7MM, in USD Million (2017–2028)
Figure 52 Market Size of B-cell NHL in the US, USD Millions (2017–2028)
Figure 53 Market Size of B-cell NHL By First-line Of Therapy in the US, USD Millions (2017–2028)
Figure 54 B-cell NHL By Relapsed and Refractory Market Size in the US, USD Millions (2017–2028)
Figure 55 Market Size of B-cell NHL in Germany, USD Millions (2017–2028)
Figure 56 Market Size of B-cell NHL By First-line Of Therapy in Germany, USD Millions (2017–2028)
Figure 57 Market Size of B-cell NHL By Relapsed and Refractory in Germany, USD Millions (2017–2028)
Figure 58 Market Size of B-cell NHL in France, USD Millions (2017–2028)
Figure 59 Market Size of B-cell NHL by first line of therapy in France, USD Millions (2017–2028)
Figure 60 B-cell NHL by Relapsed and Refractory Market Size, in France, USD Millions (2017–2028)
Figure 61 Market Size of B-cell NHL in Italy, USD Millions (2017–2028)
Figure 62 Market Size of B-cell NHL by first line of therapy in Italy, USD Millions (2017–2028)
Figure 63 B-cell NHL by Relapsed and Refractory Market Size in Italy, USD Millions (2017–2028)
Figure 64 Market Size of B-cell NHL in Spain, USD Millions (2017–2028)
Figure 65 Market Size of B-cell NHL by First line of Therapy in Spain, USD Millions (2017–2028)
Figure 66 B-cell NHL by Relapsed and Refractory Market Size in Spain, USD Millions (2017–2028)
Figure 67 Market Size of B-cell NHL in the United Kingdom USD Millions (2017–2028)
Figure 68 Market Size of B-cell NHL By First Line of Therapy in the United Kingdom in USD Millions (2017–2028)
Figure 69 B-cell NHL by Relapsed and Refractory Market Size in the United Kingdom in USD Millions (2017–2028)
Figure 70 Market Size of B-cell NHL in Japan, USD Millions (2017–2028)
Figure 71 Market Size of B-cell NHL in Japan, USD Millions (2017–2028)
Figure 72 B-cell NHL by Relapsed and Refractory Market Size in Japan in USD Millions (2017–2028)
Figure 73 Market Drivers of B-cell NHL
Figure 74 Market Barriers of B-cell NHL

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Hoffmann-La Roche
  • Novartis
  • Gilead Sciences
  • Bristol-Myers Squibb
  • MorphoSys AG
  • Pfizer
  • Merck
  • AbbVie
  • Janssen
  • Bayer
  • AstraZeneca
  • Takeda
  • Epizyme
  • Xynomic Pharmaceuticals
  • Spectrum Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll